Where there's will, there's a wayBMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7187.883 (Published 27 March 1999) Cite this as: BMJ 1999;318:883
- Roberto Lede, Argentinian Institute for Evidence Based Medicine
- Buenos Aires
Randomised controlled trials (RCTs) are often considered an expensive way to gain knowledge. Frequently, that criticism leads researchers to use less expensive and less reliable procedures to address clinical questions. It is also sometimes suggested that major trials should be limited to research centres in countries that are economically well endowed. I think it is important to challenge these views, partly because the needs of developing countries do not always coincide with those of developed countries, and partly because not all RCTs need be expensive.
Investing in RCTs that address important questions can pay dividends
The history of the Argentine episiotomy trial provides an example to illustrate this alternative view. The trial started life in 1990 at a research unit in perinatal care in Rosario, Argentina, where I was a tutor. It emerged as part of the annual training course in clinical epidemiology in perinatology, supported by the International Development Research Centre in …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.